331 related articles for article (PubMed ID: 2444727)
21. [Clinical evaluation of various tumor markers in pleural effusion and in the serum].
Jibiki K; Abe Y; Takeda M; Iwachika C; Odagiri E; Demura R; Demura H
Gan No Rinsho; 1989 Aug; 35(9):991-8. PubMed ID: 2769951
[TBL] [Abstract][Full Text] [Related]
22. [Sensitivity and specificity of CEA, Ca 15-3 and MCA levels in visceral breast carcinoma metastasis].
Delbrück H; Hagen-Aukamp C; Braun G
Strahlenther Onkol; 1990 Jul; 166(7):457-9. PubMed ID: 2200152
[TBL] [Abstract][Full Text] [Related]
23. [Tumor markers--personal experience. The use of tumor markers for cancer of digestive organs].
Ishii M
Gan To Kagaku Ryoho; 1991 May; 18(6):1059-65. PubMed ID: 1709347
[TBL] [Abstract][Full Text] [Related]
24. The use of carcinoembryonic antigen in the clinical management of patients with colorectal cancer.
Steele G; Zamcheck N
Cancer Detect Prev; 1985; 8(3):421-7. PubMed ID: 4064062
[TBL] [Abstract][Full Text] [Related]
25. Prognostic value of preoperative CEA, CA 19-9, CA 72-4, and AFP levels in gastric cancer.
Ucar E; Semerci E; Ustun H; Yetim T; Huzmeli C; Gullu M
Adv Ther; 2008 Oct; 25(10):1075-84. PubMed ID: 18821070
[TBL] [Abstract][Full Text] [Related]
26. [Clinical evaluation of CA 19-9, TPA, IAP and 5'-NPD-V as tumor markers of hepatocellular, bile duct and pancreas carcinoma].
Takahashi H; Miyazaki H; Deura M; Shimizu Y; Asukata I; Kameda H
Gan No Rinsho; 1985 May; 31(6 Suppl):623-30. PubMed ID: 2411964
[TBL] [Abstract][Full Text] [Related]
27. The role of tumour markers (CEA, TPA, CA 19-9) in colon and rectum carcinomas.
Cangemi V; Volpino P; Fiori E; Giammarco A; Piat G
J Nucl Med Allied Sci; 1987; 31(2):189-93. PubMed ID: 3476692
[No Abstract] [Full Text] [Related]
28. Clinical evaluation of five tumor marker assay in patients with lung cancer.
Mizushima Y; Tsuji H; Izumi S; Hirata H; Kin Y; Kawasaki A; Matsui S; Yano S
Anticancer Res; 1991; 11(1):91-5. PubMed ID: 2018388
[TBL] [Abstract][Full Text] [Related]
29. [Detection and clinical study of serum tumor markers in patients with colorectal cancer].
Zhao XW; Jiang B; Han CZ; Jing JX
Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):286-8. PubMed ID: 15996321
[TBL] [Abstract][Full Text] [Related]
30. [Evaluation of combined CA-19-9 and CEA assay in monitoring recurrences and metastases of colorectal cancer].
Yu BM
Zhonghua Wai Ke Za Zhi; 1992 Dec; 30(12):707-9, 777. PubMed ID: 1339738
[TBL] [Abstract][Full Text] [Related]
31. Value of plasma alpha-1-acid glycoprotein assay in the detection of human colorectal cancer: comparison with carcinoembryonic antigen.
Chu CY; Lai LT; Pokala HP
J Natl Cancer Inst; 1982 Jan; 68(1):75-9. PubMed ID: 7033631
[TBL] [Abstract][Full Text] [Related]
32. Tumor marker concentrations in normal and malignant tissues of colorectal cancer patients and their prognostic relevance.
Gebauer G; Müller-Ruchholtz W
Anticancer Res; 1997; 17(4A):2731-4. PubMed ID: 9252706
[TBL] [Abstract][Full Text] [Related]
33. Liver metastasis of colorectal cancer by protein-tyrosine phosphatase type 4A, 3 (PRL-3) is mediated through lymph node metastasis and elevated serum tumor markers such as CEA and CA19-9.
Hatate K; Yamashita K; Hirai K; Kumamoto H; Sato T; Ozawa H; Nakamura T; Onozato W; Kokuba Y; Ihara A; Watanabe M
Oncol Rep; 2008 Oct; 20(4):737-43. PubMed ID: 18813812
[TBL] [Abstract][Full Text] [Related]
34. Expression of tumour markers CA50, CEA and TPA in female breast carcinoma as related to histopathological findings and survival.
Eskelinen M; Lipponen P; Syrjänen K
Anticancer Res; 1992; 12(1):91-5. PubMed ID: 1567186
[TBL] [Abstract][Full Text] [Related]
35. [Significance of CEA and CA242 in the diagnosis of colorectal carcinoma].
Wu J; Yu H; Shao Y
Zhonghua Zhong Liu Za Zhi; 1995 Nov; 17(6):438-40. PubMed ID: 8697997
[TBL] [Abstract][Full Text] [Related]
36. [CEA, GICA, TPA, fibrinopeptide-A, gamma-GT and gastric cancer. A contribution to the rationalization of a combined assay].
Abbasciano V; Graziano L; Arcudi D; Tassinari D; Nielsen I; Sartori S
Recenti Prog Med; 1991 Oct; 82(10):517-9. PubMed ID: 1684676
[TBL] [Abstract][Full Text] [Related]
37. Serological studies on CEA, CA 19-9, STn and SLX in colorectal cancer.
Sato T; Nishimura G; Nonomura A; Miwa K; Miyazaki I
Hepatogastroenterology; 1999; 46(26):914-9. PubMed ID: 10370638
[TBL] [Abstract][Full Text] [Related]
38. [Possibilities of prognosis in cancer of the transverse colon and rectum using CEA, AFP and immunoglobulins A, M and G].
Smyslova VN
Vopr Onkol; 1987; 33(5):42-8. PubMed ID: 2438847
[TBL] [Abstract][Full Text] [Related]
39. Detection of blood-borne cells in colorectal cancer patients by nested reverse transcription-polymerase chain reaction for carcinoembryonic antigen messenger RNA: longitudinal analyses and demonstration of its potential importance as an adjunct to multiple serum markers.
Guadagni F; Kantor J; Aloe S; Carone MD; Spila A; D'Alessandro R; Abbolito MR; Cosimelli M; Graziano F; Carboni F; Carlini S; Perri P; Sciarretta F; Greiner JW; Kashmiri SV; Steinberg SM; Roselli M; Schlom J
Cancer Res; 2001 Mar; 61(6):2523-32. PubMed ID: 11289125
[TBL] [Abstract][Full Text] [Related]
40. Serum CA 242 and CEA detect different patients with recurrent colorectal cancer.
Carpelan-Holmström MA; Haglund CH; Järvinen HJ; Roberts PJ
Anticancer Res; 1996; 16(2):981-6. PubMed ID: 8687164
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
